The Association of the British Pharmaceutical Industry (ABPI) has commented on the new deal between the UK and Japan, as the UK seeks to form trade agreements with other nations in lieu of membership of the European Union.
Claire Machin, Head of International Policy at the ABPI said:
“The UK-Japan agreement provides much-needed continuity to businesses in our sector as they focus on preparations for the end of the Transition Period.
“These early deals are an opportunity for the Government to set out a future trade agenda which supports innovative British industries, encourages R&D investment and strengthens the UK’s role as a leader in life sciences. We look forward to working with them to achieve that in future agreements.”
For the pharmaceutical industry, the key aspect of the agreement is the creation of a mutual recognition agreement (MRA) for medicines, equivalent to the one currently in place between Japan and the EU. This enables easier, duplication-free trading of medicines between the two nations, and is a key ask of the ABPI for future agreements.
Read the full ABPI response for more information.